Trust Signals
Key Takeaways
- Semaglutide produced roughly 15% mean body weight loss versus 2.4% placebo in the STEP 1 RCT (n=1961), the highest-quality fat loss evidence of any peptide class.
- Tesamorelin 2 mg daily reduced visceral adipose tissue by roughly 15 to 18% in two Falutz-led NEJM trials, but is approved only for HIV lipodystrophy.
- AOD-9604 failed Phase 2 human trials for obesity; its developer discontinued the weight-loss program; its current popularity on gray-market sites is not supported by human efficacy data.
- CJC-1295 and ipamorelin amplify GH pulses but have no human RCT demonstrating clinically significant fat loss as a primary endpoint.
- Reconstituted peptide solutions degrade meaningfully within roughly 28 to 30 days at refrigerator temperature; many gray-market vials lack third-party purity confirmation, and independent assays have repeatedly found dose discrepancies and detectable impurities in research-grade peptides sold online.
What Is the Best Fat Loss Peptide Right Now?
Semaglutide is the best fat loss peptide by a wide margin when judged by human RCT evidence. Tesamorelin is the best option for visceral fat specifically in an approved clinical context. Every other peptide commonly marketed for fat loss, including AOD-9604, CJC-1295, and ipamorelin, has substantially weaker or absent human efficacy data, and that gap matters when weighing real risk against speculative benefit.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Every Major Fat Loss Peptide Graded
- How Do GLP-1 Peptides Actually Burn Fat (With Numbers)?
- Tesamorelin: The Visceral Fat Specialist
- CJC-1295 and Ipamorelin: What the GH Stack Actually Does
- AOD-9604: Why It Flopped in Humans
- What Most Pages Get Wrong About Fat Loss Peptides
- Head-to-Head: Peptides vs. Their Real Alternatives
- Stability, Purity, and Sourcing: The Formulation Gotchas
- How to Read a Peptide COA and Product Label
- FAQ
- Sources
Evidence Ledger: Every Major Fat Loss Peptide Graded
| Peptide | Best Evidence Type | Effect Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| Semaglutide | Human RCT (Phase 3, n=1961) | Significant fat and weight loss | High | Prescription only; weight returns on cessation |
| Tirzepatide | Human RCT (SURMOUNT-1, n=2539) | Significant fat and weight loss | High | Dual GIP/GLP-1; not a classical peptide analogue |
| Tesamorelin | Human RCT (2 NEJM trials, n=412 and n=273) | Visceral fat reduction | Moderate to High | Approved only for HIV lipodystrophy; off-label use is unsettled |
| CJC-1295 plus Ipamorelin | Mechanistic inference; small human PK studies | GH elevation confirmed; fat loss inferred | Low | No human RCT with fat loss as primary endpoint |
| AOD-9604 | Animal models; failed Phase 2 human trial | No significant effect in humans | Very Low | Program discontinued by developer |
| BPC-157 | Animal models only | No fat loss signal | Very Low | Healing compound, not a fat loss peptide |
| MOTS-c | Animal models; one small human study (n=10) | Possible metabolic improvement | Very Low | Mitochondrial peptide; fat loss data are preliminary |
How Do GLP-1 Peptides Actually Burn Fat (With Numbers)?
Semaglutide is a GLP-1 receptor agonist with roughly 94% amino acid homology to native GLP-1 but a half-life of approximately 165 to 184 hours (weekly dosing) due to C-18 fatty diacid attachment enabling albumin binding. Native GLP-1 has a half-life under 2 minutes. That structural change is the entire pharmacological story.
GLP-1 receptors are expressed in the hypothalamic arcuate nucleus, the vagus nerve, and the gastric enteric system. Semaglutide activates these concurrently to reduce appetite (lower caloric intake), slow gastric emptying (earlier satiety signaling), and modestly increase resting energy expenditure. In the STEP 1 trial (Wilding et al., NEJM 2021, n=1961), participants on 2.4 mg subcutaneous weekly lost a mean of 14.9% body weight versus 2.4% on placebo over 68 weeks. Roughly 86% of that weight loss was fat mass based on DEXA sub-studies.
What that mechanism does NOT prove: GLP-1 agonists do not directly oxidize fat cells. The loss is driven overwhelmingly by caloric deficit from reduced intake, not by upregulated lipolysis. This is a critical distinction when comparing to GHRH analogues, which act more directly on lipolytic pathways.
Tesamorelin: The Visceral Fat Specialist
Tesamorelin is a synthetic GHRH analogue with a trans-3-hexenoic acid modification at the N-terminus that increases resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. Native GHRH has a half-life of minutes; tesamorelin's half-life is approximately 26 to 38 minutes, enough to meaningfully extend GH pulsatility.
In Falutz et al. (NEJM 2007, n=412) and the confirmatory Falutz et al. (Journal of Acquired Immune Deficiency Syndromes, 2010, n=273) trials, tesamorelin 2 mg subcutaneous daily reduced visceral adipose tissue by approximately 15 to 18% versus placebo over 26 weeks in HIV-positive adults with lipodystrophy. IGF-1 rose by roughly 180 to 200 mcg/L from baseline. VAT returned toward baseline within 12 weeks of stopping.
Tesamorelin raises fasting glucose measurably. The trials reported higher rates of new-onset glucose abnormalities in the treatment arm versus placebo. Clinicians monitoring tesamorelin off-label must track HbA1c and fasting glucose regularly.
CJC-1295 and Ipamorelin: What the GH Stack Actually Does
CJC-1295 without DAC (Modified GRF 1-29) is a truncated GHRH analogue with 4 amino acid substitutions that improve receptor selectivity and half-life to roughly 30 minutes. The DAC version adds a Drug Affinity Complex that allows albumin binding, extending half-life to roughly 6 to 8 days but converting pulsatile GH release into a sustained elevation.
Ipamorelin is a pentapeptide GHS-R agonist that mimics ghrelin's GH-releasing action with high selectivity and minimal cortisol or prolactin stimulation compared to older GH secretagogues like GHRP-6. Preclinical pharmacology work by Raun et al. (European Journal of Endocrinology, 1998) characterized ipamorelin's selectivity profile and demonstrated GH-releasing activity in animal models, establishing it as a cleaner secretagogue than earlier compounds in its class.
The combination raises endogenous GH. GH promotes lipolysis, primarily in visceral and subcutaneous adipose tissue, via hormone-sensitive lipase activation. This is the mechanistic chain. What is absent is a human RCT showing meaningful fat loss as a primary endpoint for this combination in healthy adults. Studies showing body composition changes with therapeutic GH replacement in GH-deficient patients are not transferable to healthy individuals with normal GH axes.
AOD-9604: Why It Flopped in Humans
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone (hGH 177-191), with an added tyrosine residue. The rationale was that this region contained the lipolytic activity of hGH without the IGF-1-raising, diabetogenic effects of the full molecule.
In rodent studies, AOD-9604 reduced fat mass meaningfully. Metabolic Pharmaceuticals advanced it through Phase 1 and Phase 2 human trials. In a randomized, double-blind, placebo-controlled Phase 2 trial, oral doses ranging from 1 mg to 30 mg daily failed to produce statistically significant weight loss versus placebo over 12 weeks. The company discontinued the obesity development program. The compound later received FDA GRAS (Generally Recognized as Safe) designation as a food additive ingredient, which some gray-market marketers misrepresent as evidence of fat loss efficacy. GRAS status addresses safety classification, not therapeutic effect.
What Most Pages Get Wrong About Fat Loss Peptides
1. Conflating GH elevation with fat loss. Raising GH in a person with a normal, functioning GH axis does not produce the same fat loss seen in GH-deficient patients receiving replacement therapy. The axis has feedback mechanisms (somatostatin release, IGF-1 negative feedback) that limit the downstream effect. Most commodity pages ignore this distinction entirely.
2. Using animal data as clinical evidence. AOD-9604, BPC-157, MOTS-c, and others have compelling rodent data. Rodent fat metabolism differs from human metabolism in ways that make direct translation unreliable. Rats given supraphysiological peptide doses in controlled lab conditions are not comparable to a person injecting reconstituted gray-market product.
3. Ignoring the regain data. The withdrawal extension of STEP 1 (Wilding et al., Diabetes, Obesity and Metabolism, 2022) showed that participants who stopped semaglutide regained a mean of roughly two-thirds of their lost weight. No peptide produces durable fat loss without continued use or behavior change. This is never mentioned in listicles promoting peptides.
4. Treating all CJC-1295 products as the same. The with-DAC and without-DAC versions have different pharmacokinetics and potentially different metabolic effects. Products are frequently mislabeled in gray-market channels. A vial labeled "CJC-1295" may contain either version, or neither.
Head-to-Head: Peptides vs. Their Real Alternatives
| Comparison | Peptide | Alternative | Winner (Fat Loss Evidence) | Where Peptide Loses |
|---|---|---|---|---|
| Weight loss overall | Semaglutide 2.4 mg | Orlistat 120 mg TID | Semaglutide (15% vs roughly 3 to 5% body weight) | Cost, injection requirement, GI side effects |
| Visceral fat | Tesamorelin 2 mg | Lifestyle intervention alone | Tesamorelin for speed; lifestyle for durability | Glucose risk; VAT returns on cessation |
| GH-mediated fat loss | CJC-1295 plus ipamorelin | Therapeutic recombinant GH (GH-deficient patients) | Recombinant GH (documented efficacy in deficiency) | CJC/ipa has no RCT fat loss data in healthy adults |
| General fat loss | AOD-9604 | Diet plus resistance training | Diet plus training (evidence unambiguous) | AOD failed its own Phase 2 trial |
| Metabolic improvement | Tirzepatide | Semaglutide | Tirzepatide (SURMOUNT-1 showed roughly 20% body weight loss, higher than STEP 1) | Tirzepatide wins on magnitude; both require prescription |
Stability, Purity, and Sourcing: The Formulation Gotchas
Why lyophilized peptides degrade faster than people expect. After reconstitution with bacteriostatic water, peptide bonds are exposed to hydrolysis. Methionine-containing peptides (some GHRH analogues) also oxidize at that residue, changing receptor binding affinity. Even properly refrigerated solutions degrade meaningfully over 28 to 30 days. Freeze-thaw cycles are particularly damaging because ice crystal formation mechanically disrupts the three-dimensional structure that determines receptor specificity.
The purity problem in gray-market peptides. Independent assays of research-grade peptides sold online have repeatedly found dose discrepancies and detectable impurities in a meaningful proportion of samples. These analyses, conducted by academic and commercial analytical chemistry groups using HPLC and mass spectrometry, consistently identify products containing less than stated purity, truncated sequences with unknown pharmacology, or endotoxin levels unsuitable for injection. No single study is cited here to avoid misrepresentation, but the pattern across published quality-assessment work is consistent: gray-market peptide purity is unreliable without independent verification.
Bacteriostatic water versus sterile water. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and allows multi-dose use for up to 28 days. Sterile water has no preservative and should be discarded after a single use. Using sterile water in a multi-dose vial creates contamination risk within days. Many inexperienced users make this error.
How to Read a Peptide COA and Product Label
A legitimate Certificate of Analysis for an injectable research peptide should contain all of the following:
| COA Element | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Greater than 98% for injectables | No purity listed, or purity below 95% |
| Mass spectrometry identity | Molecular weight confirms correct peptide | Identity "confirmed by HPLC" alone (insufficient) |
| Endotoxin (LAL test) | Below 1 EU/mg for injectable use | Not tested or result absent |
| Testing lab | ISO 17025 accredited, independent (not in-house) | Lab name absent or same as vendor |
| Lot number | Matches product vial label | Generic COA not matched to specific lot |
| Peptide sequence | Amino acid sequence listed | Sequence absent; only trade name listed |
Dosing reference for the most evidenced peptides (for orientation, not prescription):
| Peptide | Trial-Used Dose | Route | Frequency in Trials |
|---|---|---|---|
| Semaglutide | 2.4 mg (STEP 1) | Subcutaneous | Weekly |
| Tesamorelin | 2 mg (Falutz trials) | Subcutaneous | Daily |
| Ipamorelin (human PK only) | 200 mcg (PK study) | Subcutaneous | Twice to three times daily in practice |
These are trial doses, not recommendations. Semaglutide and tesamorelin require a licensed prescriber in the United States. Neither should be sourced from unregulated vendors.
FAQ
What is the best fat loss peptide overall?
Semaglutide (a GLP-1 receptor agonist) has the strongest human RCT evidence, producing roughly 15% body weight loss in the STEP 1 trial. Tesamorelin is second for visceral fat specifically. Peptides like CJC-1295 and ipamorelin have far weaker human evidence for fat loss and should be ranked below both.
Does AOD-9604 actually work for fat loss?
AOD-9604 showed fat-reducing activity in rodent models but failed to produce statistically significant weight loss in human clinical trials. Its developer, Metabolic Pharmaceuticals, discontinued the obesity program after Phase 2 results were negative. It is commonly sold as a research compound with claims that outstrip the evidence.
What is the difference between CJC-1295 and ipamorelin for fat loss?
CJC-1295 is a GHRH analogue that extends the pulse of growth hormone release. Ipamorelin is a GHS-R agonist (ghrelin mimetic) that triggers a separate GH pulse pathway. Combined, they produce additive GH release. Neither has human RCT evidence specifically demonstrating meaningful fat loss; any benefit is inferred from GH physiology, which is indirect evidence at best.
How does tesamorelin reduce visceral fat?
Tesamorelin is a stabilized GHRH analogue that raises IGF-1 and endogenous GH. In HIV-associated lipodystrophy trials (Falutz et al., NEJM 2007 and Falutz et al., JAIDS 2010), 2 mg subcutaneous daily reduced visceral adipose tissue by roughly 15 to 18% versus placebo over 26 weeks. The mechanism is enhanced lipolysis in visceral adipocytes driven by GH signaling.
Are peptide fat loss results permanent?
No. In GLP-1 agonist trials, participants who discontinued semaglutide regained roughly two-thirds of lost weight (Wilding et al., Diabetes, Obesity and Metabolism, 2022 withdrawal extension). For GHRH analogues like tesamorelin, visceral fat returned toward baseline within weeks of stopping. Fat loss from peptides is not permanent without continued use or lifestyle maintenance.
What peptides are FDA-approved for fat or weight management?
Semaglutide (Wegovy) is FDA-approved for chronic weight management. Tesamorelin (Egrifta) is FDA-approved specifically for HIV-associated lipodystrophy, not general obesity. Tirzepatide (Zepbound) is approved for obesity but is a dual GIP/GLP-1 receptor agonist. No other fat loss peptides sold online hold FDA approval for weight loss.
Can you use CJC-1295 without DAC for fat loss?
CJC-1295 without DAC (also called Modified GRF 1-29) has a short half-life of roughly 30 minutes and must be injected close to sleep when GH pulses are naturally highest. The DAC version has a half-life of roughly 6 to 8 days but produces a blunted, sustained GH elevation rather than a physiological pulse. Neither form has human RCT fat loss data.
What are the main side effects of fat loss peptides?
GLP-1 agonists: nausea, vomiting, gastroparesis risk, pancreatitis (rare), potential thyroid C-cell risk. GHRH analogues: water retention, joint pain, increased fasting glucose, carpal tunnel symptoms. AOD-9604 and BPC-157: side effect profiles are poorly characterized in humans given limited trial data. Injection-site reactions apply to all subcutaneous peptides.
How do I know if a peptide product is pure?
Request a Certificate of Analysis from an independent, ISO-accredited lab showing HPLC purity above 98%, mass spec identity confirmation, and endotoxin testing below 1 EU/mg for injectable use. Peptides sold without independent third-party COAs should not be injected. Independent quality-assessment work has consistently found dose discrepancies and detectable impurities in a meaningful proportion of gray-market research peptide samples.
Does BPC-157 cause fat loss?
There is no credible human evidence that BPC-157 reduces body fat. It has demonstrated tissue-healing effects in rodent models. Any fat loss attribution is anecdotal. BPC-157 is not an appropriate choice if fat loss is the primary goal.
What is the best peptide stack for fat loss?
The most evidence-supported combination is a GLP-1 agonist under medical supervision. If using research peptides, the CJC-1295 plus ipamorelin combination is most commonly discussed in practice, but clinical fat loss data remain indirect and limited. Stacking multiple research peptides amplifies unknown interaction risks without proportional evidence of benefit.
How should fat loss peptides be stored?
Lyophilized (freeze-dried) peptides should be stored at 2 to 8 degrees Celsius and protected from light. Once reconstituted with bacteriostatic water, most peptides degrade meaningfully within 28 to 30 days even refrigerated, due to hydrolysis and oxidation. Do not freeze reconstituted peptide solutions, as ice crystal formation disrupts tertiary structure.
Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002. (STEP 1 trial)
- Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
- Falutz J, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension." Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322.
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1)
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.
- Heffernan MA, et al. "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 177-191." International Journal of Obesity. 2001;25(10):1442-1449.
- Metabolic Pharmaceuticals. AOD-9604 Phase 2 clinical trial data summary. Publicly disclosed in investor communications, 2004 to 2007.
- FDA GRAS Notice No. GRN 000579. AOD9604. United States Food and Drug Administration. 2014.
- Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.